The Intensity of Hospital Care Utilization by Dutch Patients With Lung or Colorectal Cancer in their Final Months of Life

Yvonne de Man, MSc1, Femke Atsma, PhD1, Mariska G. Oosterveld-Vlug, PhD2, Linda Brom, PhD3, Bregje D. Onwuteaka-Philipsen, PhD2, Gert P. Westert, PhD1, and A. Stef Groenewoud, PhD1

Abstract
Understanding the overuse and underuse of health-care services in the end-of-life (EoL) phase for patients with lung cancer (LC) and colorectal cancer (CRC) is important, but knowledge is limited. To help identify inappropriate care, we present the health-care utilization profiles for hospital care at the EoL of patients with LC (N = 25,553) and CRC (N = 14,911) in the Netherlands between 2013 and 2015. An administrative database containing all in-hospital health-care activities was analyzed to investigate the association between the number of days patients spent in the emergency department (ED) or intensive care unit (ICU) and their exposure to chemotherapy or radiotherapy. Fewer patients received hospital care as death neared, but their intensity of care increased. In the last month of life, the average numbers of hospital bed days, ICU days, and ER contacts were 9.0, 5.5, and 1.2 for patients with CRC, and 8.9, 6.2, and 1.2 for patients with LC in 2015. On the other hand, the occurrence of palliative consultations ranged from 1% to 4%. Patients receiving chemotherapy 6 months before death spent fewer days in ICU than those who did not receive this treatment (odds ratios: CRC = 0.6 [95% confidence interval: 0.4-0.8] and LC = 0.7 [0.5-0.9]), while those receiving chemotherapy 1 month before death had more ED visits (odds ratios: CRC = 17.2 [11.8-25.0] and LC = 15.8 [12.0-20.9]). Our results showed that patients who were still receiving hospital care when death was near had a high intensity of care, yet palliative consultations were low. Receiving chemotherapy or radiotherapy in the final month of life was significantly associated with more ED and ICU contacts in patients with LC.

Keywords
colorectal cancer, lung cancer, hospital care, end-of-life, undertreatment, overtreatment

Received May 09, 2018. Received revised November 19, 2018. Accepted for publication April 03, 2019.

Introduction
Lung cancer (LC) and colorectal cancer (CRC) are 2 of the 5 most common types of cancer in the Netherlands,1 with 12,600 and 15,000 new patients, respectively, diagnosed in 2015. With 5-year survival rates of 18% (LC) and 58% (CRC), survival is low.1 Furthermore, patients with LC and CRC have the second and third highest hospital care costs of all patients with cancer.2

Due to screening programs, more patients with cancer are identified at earlier disease stages. Cancer is increasingly becoming a chronic disease as a result of new chemotherapies and targeted therapies, meaning that the end-of-life (EoL)
phase and the process of dying are longer and more gradual. The early detection of the palliative phase, advance care planning (ACP), and well-considered EoL care are therefore becoming increasingly important; however, we know that medical care can be both overused and underused.\(^3\) It can be overused in patients with cancer who receive aggressive treatments during the EoL phase, which increases their burden while decreasing their quality of life.\(^4,5\) The underuse of health care, for instance not having timely EoL discussions, is associated with higher costs and a lower quality of death and dying.\(^6\)

Analyzing the health-care utilization (HCU) of a patient group forms the first crucial step toward improving their health care and is a tool for the identification of the overuse and underuse of medical care. Here, we aim to present the HCU profiles (HCUP) of patients with LC and CRC using activity-based hospital data. This will provide complementary and contrasting information to the analysis of diagnosis-related group (DRG)–based hospital data, which was previously performed by Bekelman et al.\(^7\)

### Materials and Methods

#### Study Population and Selection

This population-based cohort study includes insured Dutch persons (99% of the Dutch population)\(^8\) who died in 2013, 2014, or 2015 with a diagnosis of LC and/or CRC for whom hospital medical care had been registered. The patients were included as patients with LC if they had been diagnosed with non-small-cell lung carcinoma or small-cell lung cancer, neoplasm bronchus lung, or small- and large-cell bronchus carcinoma. Patients with CRC were included if they had been diagnosed with colorectal malignancy or malignant neoplasm of the colon. Patients under 18 at the time of death or those who lacked a valid citizen service number and post code were excluded from the analysis.

#### Data

A national database of administrative hospital data at the health-care activity level was used in the analyses presented here. These activities are registered by all Dutch hospitals (8 academic and 92 general hospitals) and by more than 300 independent treatment centers. The data also contained information regarding the institution providing the care as well as the age and gender of the patients. For 2013 and 2014, the data covered 95% of the delivered and billable care. For 2015, this was approximately 70% due to the administrative delay in registries after care had been given.

#### Expert Panel

Five medical experts were involved: 2 pulmonologists/oncologists and 3 experts specializing in internal medicine and oncology. All were specialized in palliative medicine. First, individual in-depth interviews were conducted with 4 experts using an interview guide to gain insights into their current practice and the background and reasons for the HCU patterns of Dutch patients with CRC or LC in the EoL phase. During the analysis phase, the experts classified each health-care activity into meaningful clusters (Table 1) and compared the volume and intensity of EoL HCU to their experiences of daily practice. Also, the experts indicated which types of care had been registered too frequently in their opinion and what would be potential areas for improvement. Finally, the experts argued that unplanned and unwanted admissions such as ED contacts and days in ICU were important to investigate further. They formulated an additional question regarding the association between unwanted admissions and chemotherapy and radiotherapy. It was not possible to identify avoidable or unwanted hospital bed days from the available data; therefore, this study was focused on ICU days and ED contacts.

#### Clustering Health-Care Activities

More than 13 000 different health-care activities were included in the database, many of which can be grouped together. The experts were therefore asked to define the important and relevant health-care clusters for the EoL phases of patients with CRC and LC separately; it was not necessary to identify the same categories for the 2 illnesses. Subsequently, 2 teams of experts appointed the 75% most frequently occurring health-care activities within each specialism to one of these categories. The process of defining the categories was iterative, meaning that within and between the 2 teams, the categories were adjusted and refined during the clustering process until a consensus was reached. One of the experts checked and finalized the clustering. The health-care activity codes for which no description was available (<1%) and the additional costs for
laboratory work, ICU admissions, house visits, or travel expenses were excluded because HCU, not health-care costs, were the focus of this investigation. Also, postmortem examinations were excluded from the clustering as these were not part of the EoL HCU.9

Analyses

The intensity of the HCU was examined by calculating the percentage of patients who received care described within the clusters and determining how often these care activities were performed on average per patient per month in the last 6, 3, and 1 month(s) before death. The associations between radiotherapy or chemotherapy and ICU days or ED contacts were also analyzed using a $2 \times 2$ frequency table, for which the corresponding odds ratios (OR) and 95% confidence intervals (CI) were calculated. The analyses were performed using SAS Enterprise Guide 9.2.

Table 1. Clusters of Health-Care Activities and Descriptions.

| Category                                      | Description                                                                                                                                 |
|-----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| Inpatient days                                | A first or subsequent clinical admission, classes A, B, and C  Adam delante los servicios relacionados con los cuidados hospitalarios de primera o segunda mención, clases A, B, y C  |
| ICU days                                       | Low, medium, and high care in the ICU  Adam delante los cuidados intensivos de bajo, medio, y alto nivel  |
| Outpatient days                               | Life support in the ED  Atención de soporte en la ED  |
| Ambulatory visit                              | A first or return visit  Un primer o segundo viaje ambulatorio  |
| Specialty care consultations                  | Specific health-care activity describing a palliative consultation  Actividad de atención sanitaria específica que describa una consulta paliativa  |
| Palliative care consultation                  | Specific health-care activity describing a palliative consultation  Actividad de atención sanitaria específica que describa una consulta paliativa  |
| Multidisciplinary consultation                | Co-treatments with other specialists, (clinical) multidisciplinary consultation and activities  Co-tratamientos con otros especialistas, (clínico) multidisciplinario consulta y actividades  |
| Consultation                                  | Consultations between patient and specialist, face-to-face or by telephone  Consultaciones entre el paciente y el especialista, de cara a cara o por teléfono  |
| Allied and therapeutic care, per 15 minutes   | All allied care and consultations, including physiotherapists, nutritionists, nurse practitioners, psychologists, social workers, optometrists, and geriatric rehabilitation  Todos los cuidados y consultaciones relacionados con la atención, incluyendo fisioterapeutas, dietistas, enfermeras, psicólogos, trabajadores sociales, oftalmólogos, y rehabilitación geriátrica  |
| Diagnostic tests                              | All lab tests regarding hematology and small chemistry  Todos los ensayos de laboratorio referentes a hematoquímica y química pequeña  |
| Laboratory test                               | All lab tests regarding hematology and small chemistry  Todos los ensayos de laboratorio referentes a hematoquímica y química pequeña  |
| Noninvasive diagnostic test—pathological      | Microbiological, histological and pathological (laboratory) tests  Microbiológicos, histológicos y patológicos (laboratorio) tests  |
| Other noninvasive diagnostics                 | CGA, spirogram tests, interpreting radiology results, preassessments, blood pressure measurement, audiometric tests, and so on  CGA, spirogram tests, interpretación de resultados de radiología, preasesesiones, medición de presión arterial, pruebas audiométricas  |
| Invasive diagnostics                          | Includes colonoscopies and bronchoscopies, as well as biopsies and diagnostic punctures  Incluye colonoscopias y broncoscopias, así como biopsias y pruebas diagnósticas  |
| Imaging                                       | Ultrasounds and X-rays, Doppler, duplex, EEG  Ultrasonidos y radiografías, Doppler, duplex, EEG  |
| Conventional radiology                        | Ultrasounds and X-rays, Doppler, duplex, EEG  Ultrasonidos y radiografías, Doppler, duplex, EEG  |
| CT scan                                       | CT scans  Escansos de CT  |
| MRI scan                                      | MRI scans  Escansos de MRI  |
| PET scan                                      | PET scans  Escansos de PET  |
| Nuclear scan other than PET                   | SPECT and radioactive isotope tests  SPECT y tests de isótopos radiactivos  |
| Procedures and treatments                     | Includes therapies as cisplatin, oxaliplatin, gemcitabine, docetaxel, and irinotecan  Incluye terapias como cisplatino, oxaliplato, gemcitabina, docetaxilo y irinotecano  |
| Chemotherapy                                  | Includes therapies as cisplatin, oxaliplatin, gemcitabine, docetaxel, and irinotecan  Incluye terapias como cisplatino, oxaliplato, gemcitabina, docetaxilo y irinotecano  |
| CRC/LC surgery                                | Surgeries registered under diagnosis codes specified in Table 1a and 1b, including tumor resection, tracheotomy, and therapeutic biopsies  Cirugías registradas bajo códigos de diagnóstico especificados en la Tabla 1a y 1b, incluyendo resecciones de tumor, traqueotomía, y biopsias terapéuticas  |
| Non-CRC/LC surgery                            | Surgeries other than the aforementioned, for instance, heart transplants; hip replacements; cataract, and hernia surgeries; and resections, reconstructions, and therapeutic biopsies  Cirugías diferentes a las mencionadas, por ejemplo, trasplantes de corazón; reemplazos de cadera; cirugías de cataratas y hernias; y resecciones, reconstrucciones, y biopsias terapéuticas  |
| Biologics                                      | Includes therapies such as bevacizumab, rituximab, and gefitinib  Incluye terapias como bevacizumab, rituximab, y gefitinib  |
| Radiotherapy                                  | Radiation and radiotherapy fractions  Radiación y fracciones de radioterapia  |
| Other (care and items)                        | Pre- and post-surgery/chemotherapy/radiotherapy care, dental work, devices and implants (pacemaker, Steffeeplate, shunt), prosthetics, dialysis, injections, catheters, and so on  Cuidados pre y post-operatorio/terapia quimioterapéutica/radioterapia, trabajo dental, dispositivos e implantes (pacemaker, Steffeeplate, shunt), prótesis, diálisis, inyecciones, catéteres, y así sucesivamente  |

Table 2. Baseline Characteristics of All Patients with Lung or Colorectal Cancer who Died, 2013 to 2015.

|                   | Lung Cancer, N = 25 533 | Colorectal Cancer, N = 14 911 |
|-------------------|-------------------------|------------------------------|
| Total             |                         |                              |
| Gender, %         |                         |                              |
| Male              | 15 324 (60.0%)          | 8494 (56.5%)                 |
| Female            | 10 209 (40%)            | 6417 (43.5%)                 |
| Mean age at death |                         |                              |
| Male              | 70.6                    | 71.6                         |
| Female            | 67.1                    | 72.1                         |

Results

Patient Characteristics

The characteristics of the 25 533 patients with CRC and 14 911 patients with LC included in this study are presented in Table 2.
For both CRC and LC, more males than females passed away in the years 2013 to 2015.

**Health-Care Utilization Profiles**

The main clusters of health-care activities for patients with CRC and LC are presented in Table 1, while Table 3 shows the HCUP for these patients by cluster over 3 different time periods: 6 months, 3 months, and 1 month before death. It displays the proportion of patients who received a certain type of care and the average number of times they received it each month. In all 3 years, the 3 most frequently registered healthcare activities for patients with both CRC and LC during the EoL phase were ambulatory visits, laboratory tests, and conventional radiology. Overall, the number of patients receiving hospital care decreased as their death neared, although the intensity of care per month increased for those still receiving it.

In 2015, during their last 6 months of life, 55.2% of patients with CRC and 57.2% of patients with LC were admitted to hospital (not including ICU and ER admissions). In the last month of life, these proportions decreased to 18.9% and 21.4%, respectively, with an average stay of 9 hospital bed days. For patients who visited the ICU (2%-3%) and the ED (13%-16%) during their last month of life, the numbers of ICU days and ED contacts during this period were 5.5 days and 1.2 times, respectively, for patients with CRC and 6.2 days and 1.2 times for patients with LC.

Less than 2% of all patients had a palliative care team consultation in their last month of life (Table 3), while up to 20% of the patients with CRC and 23% of the patients with LC had a (multidisciplinary) consultation with their health-care specialist in this timeframe.

During the last 6 months of life, up to 66% of the patients with CRC and 79% of the patients with LC underwent conventional radiology. A total of 56% to 64% of patients with CRC and 61% to 66% for patients with LC received a computed tomography (CT) scan during this period, which dropped to 10% to 14% for CRC and 12% to 16% for LC during the last month of the patient’s life.

During their last 6 months of life, a small number of patients received cancer-related surgery, representing 9% of the patients with CRC and 1% of the patients with LC. No more than 1% of patients with LC received biologics, although 13% to 15% of patients with CRC received these treatments throughout the whole EoL phase. The opposite was true for radiotherapy, as up to 31% of the patients with LC received this treatment compared to just 13% of patients with CRC in the last 6 months of life. Overall, in the last month of life, we found that a very low percentage of patients underwent cancer-specific treatments and procedures.

**Association Between Chemotherapy/Radiotherapy and ICU Contacts**

Patients receiving chemotherapy 6 months before their death spent fewer days in the ICU than patients who did not undergo this treatment. We observed that, in the last month of life, patients with LC undergoing chemotherapy were admitted to the ICU (OR = 2.9, 95% CI = 1.6-5.2) more often than those who did not receive chemotherapy during this period. Patients with LC receiving radiotherapy in their last month of life were significantly more frequently admitted to the ICU than patients who did not undergo this treatment (OR = 2.7, 95% CI: = 1.3-5.6).

**Discussion**

We revealed that a substantial number of patients with LC and CRC received highly intensive treatments during their EoL phase. Receiving chemotherapy or radiotherapy in the last month of life was found to be strongly associated with increased ER and ICU contacts in patients with LC.

Our results regarding hospital admissions are comparable to those of Bekelman et al who reported that 7% of elderly Dutch patients who died of cancer in 2010 spent 1 or more day(s) in ICU during their last 30 days of life, while 42% were hospitalized in an acute-care hospital. They also found that ICU admissions were more than twice as common in the United States than in the other 6 reporting countries for patients with cancer, including the Netherlands. Teno et al reported that 29.2% of all (Medicare-supported) patients with cancer in the United States were admitted to the ICU during their last 30 days of life (data from 2009). These findings were substantially higher than those of the present study (3% to 5%); however, the Netherlands has one of the lowest rates of ICU admissions among the 8 countries investigated by Teno et al. Although these findings show that HCU during the EoL phase is lower in the Netherlands than in other countries, overuse (or underuse) could still be present.

The medical experts included in this study indicated that the HCUPs we identified corresponded with their experience of daily oncological practice, describing them as “shockingly intense.” According to them, the potential areas for improvement in EoL care are to reduce the high number of admissions to the ICU and ER, to reduce the number of patients receiving a...
| Months before death | 6   | 3   | 1   | 6   | 3   | 1   | 6   | 3   | 1   |
|---------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| **Inpatient days**  |     |     |     |     |     |     |     |     |     |
| Hospital bed days   | 3235| 63  | 1.8 | 2502| 49  | 1.8 | 3164| 70  | 2.3 |
| ICU days            | 471 | 9.0 | 1.0 | 377 | 7.0 | 1.0 | 287 | 6.3 | 1.0 |
| **Outpatient days** |     |     |     |     |     |     |     |     |     |
| ED visit            | 2613| 51  | 0.2 | 1937| 38  | 0.2 | 977 | 19  | 0.2 |
| Ambulatory visit    | 4788| 94  | 0.5 | 4018| 79  | 0.5 | 2079| 40  | 0.5 |
| **Specialty care consultations** |     |     |     |     |     |     |     |     |     |
| Palliative care consultation | 201 | 4   | 0.3 | 162 | 3   | 0.3 | 100 | 2   | 0.2 |
| Consultation        | 2924| 57  | 0.4 | 2139| 42  | 0.4 | 934 | 18  | 0.4 |
| Paramedic and therapeutic care, per 15 min | 2015 | 39  | 3.5 | 4816 | 94  | 1.5 | 377 | 9.1 | 1.5 |
| **Diagnostic tests** |     |     |     |     |     |     |     |     |     |
| Laboratory test     | 4459| 87  | 1.9 | 3673| 72  | 1.9 | 2012| 39  | 1.9 |
| Noninvasive diagnostic test—pathological | 3823| 75  | 1.1 | 2942| 58  | 1.1 | 1485| 30  | 1.1 |
| Other noninvasive diagnostics | 2651| 52  | 0.3 | 1706| 33  | 0.3 | 765 | 15  | 0.3 |
| Invasive diagnostics | 1907| 37  | 0.3 | 1068| 21  | 0.3 | 816 | 19  | 0.3 |
| **Imaging**         |     |     |     |     |     |     |     |     |     |
| Conventional radiology | 3388| 66  | 0.4 | 2485| 49  | 0.4 | 1287| 25  | 0.4 |
| CT scan             | 3248| 63  | 0.4 | 2101| 41  | 0.4 | 691 | 14  | 0.4 |
| MRI scan            | 686 | 13  | 0.2 | 390 | 8   | 0.2 | 97  | 2   | 0.2 |
| PET scan            | 275 | 5   | 0.2 | 125 | 2   | 0.2 | 26  | 1   | 0.2 |
| Nuclear scan other than PET | 208 | 4   | 0.2 | 103 | 2   | 0.2 | 21  | 0.2 | 0.2 |
| **Procedures and treatments** |     |     |     |     |     |     |     |     |     |
| Chemotherapy        | 1333| 26  | 0.7 | 792 | 16  | 0.7 | 236 | 5   | 0.7 |
| CRC surgery         | 440 | 9   | 0.2 | 248 | 5   | 0.2 | 92  | 2   | 0.2 |
| Non-CRC surgery     | 1097| 22  | 0.3 | 584 | 11  | 0.3 | 175 | 3   | 0.3 |
| Biologics           | 654 | 13  | 0.3 | 385 | 8   | 0.3 | 118 | 2   | 0.3 |
| Radiotherapy        | 667 | 13  | 1.5 | 424 | 8   | 1.5 | 142 | 3   | 1.5 |
| Other (care and items) | 3653| 72  | 1.7 | 2830| 55  | 1.7 | 1542| 30  | 1.7 |

(continued)
| Table 3. (continued) |
|----------------------|
| Lung cancer          | 2013 (N = 9124) | 2014 (N = 9764) | 2015 (N = 6643) |
| **Months before death** |      |      |      |
|                      | 6    | 3    | 1    | 6    | 3    | 1    | 6    | 3    | 1    |
|                      | N%  | N%  | I  | N%  | N%  | I  | N%  | N%  | I  |
| Inpatient days       |      |      |    |      |      |    |      |      |    |
| Hospital bed days    | 5978 | 66  | 1.7 | 4714 | 52  | 3.3 | 2712 | 30  | 9.0 |
| ICU days             | 435  | 5   | 0.8 | 344  | 4   | 1.8 | 257  | 3   | 5.9 |
| Outpatient days      |      |      |    |      |      |    |      |      |    |
| ED visit             | 5200 | 57  | 0.2 | 3998 | 44  | 0.4 | 2188 | 24  | 1.2 |
| Ambulatory visit     | 8644 | 95  | 0.5 | 7467 | 82  | 0.7 | 4209 | 82  | 0.7 |
| Specialty care consultations |      |      |    |      |      |    |      |      |    |
| Palliative care consultation | 264 | 3   | 0.3 | 229  | 3   | 0.5 | 167  | 2   | 1.5 |
| Multidisciplinary consultation | 4754 | 52  | 0.4 | 3616 | 40  | 0.7 | 2036 | 22  | 2.0 |
| Consultation         | 551  | 60  | 0.3 | 4196 | 47  | 0.6 | 2041 | 22  | 1.4 |
| Paramedic and therapeutic care, per 15 min | 4043 | 4.2 | 3023 | 3.3 | 1.2 | 4639 | 4.2 | 1.7 |
| Diagnostic tests     |      |      |    |      |      |    |      |      |    |
| Laboratory test      | 7755 | 85  | 8.1 | 6317 | 69  | 15.1 | 3151 | 39  | 46.6 |
| Noninvasive diagnostic test—pathological | 7016 | 77  | 0.9 | 5386 | 59  | 1572 | 30  | 5.6 |
| Other noninvasive diagnostics | 5577 | 62  | 0.4 | 3775 | 41  | 0.6 | 1764 | 19  | 1.7 |
| Invasive diagnostics | 4081 | 45  | 0.3 | 2353 | 26  | 0.6 | 868  | 10  | 1.6 |
| Imaging              |      |      |    |      |      |    |      |      |    |
| Conventional radiology | 7218 | 79  | 0.4 | 5664 | 62  | 0.7 | 2906 | 32  | 2.0 |
| CT scan              | 5920 | 65  | 0.3 | 3993 | 44  | 0.6 | 1485 | 16  | 0.6 |
| MRI scan             | 2423 | 27  | 0.3 | 1396 | 15  | 0.5 | 406  | 4   | 0.1 |
| PET scan             | 1795 | 20  | 0.2 | 808  | 9   | 0.3 | 170  | 2   | 0.3 |
| Nuclear scan other than PET | 1295 | 14  | 0.2 | 634  | 7   | 0.4 | 157  | 2   | 0.3 |
| Procedures and treatments |      |      |    |      |      |    |      |      |    |
| Chemotherapy         | 2724 | 30  | 0.8 | 1667 | 18  | 1.2 | 549  | 6   | 2.7 |
| LC surgery           | 87   | 1   | 0.2 | 47   | 1   | 0.4 | 19   | 0   | 1.4 |
| Non-LC surgery       | 1355 | 15  | 0.2 | 688  | 9   | 0.4 | 199  | 2   | 1.3 |
| Biologics            | 128  | 1   | 0.4 | 75   | 1   | 0.7 | 20   | 0   | 1.2 |
| Radiotherapy         | 2977 | 31  | 1.6 | 1898 | 21  | 2.4 | 707  | 8   | 5.1 |
| Other (care and items) | 6181 | 68  | 1.4 | 4732 | 52  | 2.6 | 2452 | 27  | 8.5 |

Abbreviations: CRC, colorectal cancer; CT, computed tomography; ED, emergency department; I, Intensity; ICU, intensive care unit; LC, lung cancer; MRI, magnetic resonance imaging; PET, positron emission tomography.

*Intensity is the average number of treatments per patient per month for the patients who received a particular treatment.
CT scan and the overall number of scans each patient receives, and to increase the number of palliative care consultations held with patients. We will discuss each of these themes and their level of appropriateness below.

Unwanted hospital admissions may be necessitated by a prolonged treatment during the EoL phase, as doctors may find it difficult to cease high-impact treatments such as chemotherapy and biological treatment in a timely manner and might not be able to prevent such admissions.

We argue that unplanned and even unwanted admissions could be prevented by timely discussions regarding EoL care or ACP. Palliative care consultations are a means of giving patients a more appropriate level of care, increasing the number of palliative care consultations held during the EoL phase, and to increase the quality of life and survival rates in comparison to standard care and significantly lowering health-care costs. Despite these benefits, there is currently little evidence to indicate whether palliative care interventions implemented in the hospital, home, or outpatient clinic are more effective than standard care practices at reducing ED visits among patients with cancer during their EoL phase.

Unfortunately, the number of patients receiving palliative care consultations in our study was exceptionally low. One explanation for this might be that, in the Dutch health-care system, the DRG data on palliative consultations are only registered as palliative care when a multidisciplinary team is actively providing palliative care, there has been at least 1 clinical or ambulant consultation, and the patient is solely receiving palliative care with no other curative treatments. A palliative consultation can be registered as a health-care activity; however, when the activity is not registered as palliative care, it is not sent to the database we used for our analyses. Although the number of palliative teams in Dutch hospitals is increasing, supportive care specialists are only involved in the care of 12% of non-sudden-death patients during their last month of life. Also, other reported data suggest that 20% to 25% of a representative sample of Dutch patients with CRC and LC had a palliative treatment aim in the 3 months before their deaths as recorded by their general practitioners. The percentage of patients who receive palliative consultations and the total number of these consultations might therefore be higher than our results suggest, although they are still likely to be relatively uncommon.

Our results suggest that high-impact treatments are associated with an increase in both days spent in the ICU in the last month of life for patients with LC and the number of ED contacts made throughout the entire EoL phase for both patients with LC and CRC. We cannot conclude that these treatments are inappropriate in the EoL phase on the basis of this study.

Table 4. Number of Patients With ED Contacts or ICU Days and the Number of Patients who Underwent Radiotherapy or Chemotherapy in 2015.

|                      | Chemotherapy, N (%) | No chemotherapy, % | Crude OR [95%CI] | Radiotherapy, % | No radiotherapy, % | Crude OR [95%CI] |
|----------------------|---------------------|-------------------|------------------|----------------|-------------------|------------------|
| **Colorectal cancer** |                     |                   |                  |                |                   |                  |
| Last 6 months of life|                     |                   |                  |                |                   |                  |
| ≥1 ED-contact        | 610 (54.1)          | 1174 (39.2)       |                  |                |                   |                  |
| No ED-contact         | 517 (45.9)          | 1822 (60.8)       | **1.8 [1.6-2.1]**| 213 (53.8)     | 2124 (57.0)       | **1.1 [0.9-1.4]**|
| ≥1 ICU-day(s)        | 44 (3.9)            | 204 (68.6)        |                  |                |                   |                  |
| No ICU-day            | 1083 (96.1)         | 2792 (93.2)       | **0.6 [0.4-0.8]**| 373 (94.2)     | 3500 (93.9)       | **1.0 [0.6-1.5]**|
| N = 136              | N = 3987           |                   |                  | N = 50         | N = 4073          |                  |
| **Lung cancer**       |                     |                   |                  |                |                   |                  |
| Last 6 months of life|                     |                   |                  |                |                   |                  |
| ≥1 ED-contact         | 93 (68.4)           | 447 (11.2)        |                  |                |                   |                  |
| No ED-contact         | 43 (31.6)           | 3540 (88.8)       | **17.2 [11.8-25.0]**| 30 (60.0)     | 3556 (87.3)       | **4.6 [2.6-8.1]**|
| ≥1 ICU-day(s)        | 6 (4.4)             | 116 (2.9)         |                  |                |                   |                  |
| No ICU-day            | 130 (95.6)          | 3871 (97.1)       | **1.5 [0.7-5.6]**| 47 (94.0)      | 3955 (97.1)       | **2.1 [0.7-6.9]**|
| N = 1969             | N = 4674           |                   |                  | N = 1420       | N = 5223          |                  |
| **Abbreviations:** CI, confidence interval; ED, emergency department; ICU, intensive care unit; OR, odds ratio. Bold face values – Level of significance \( p < 0.05 \).
however, as more information regarding the treatment aims and patient preferences would be required to make this determination. The association we found could reflect 2 nonexclusive contrasting possibilities: Patients receiving chemotherapy may end up in the ED/ICU more often than those who do not receive chemotherapy/radiotherapy due to an increase in complications, or their ED/ICU admission may lead to chemotherapy treatments; for instance, if a palliative treatment aim is determined after their admission. Studies have shown conflicting and inconclusive results regarding (palliative) chemotherapy\textsuperscript{22-24}; however, regardless of the direction of this association, our data suggest that high-intensity care (whether chemotherapy or an ICU admission) is associated with the patient receiving other highly intensive care. Medical specialists should consider the intensity of these treatments when discussing them with their patients. Bearing in mind that 80% of patients would prefer to die at home\textsuperscript{25,26} but only 61% actually do,\textsuperscript{26} we must ask whether this trend is acceptable.

Although they are important for the initial staging process of the cancer with acceptable cost-effectiveness parameters and even cost savings,\textsuperscript{27} a CT scan might be unnecessary if it will not make a difference to the subsequent treatment. Schnipper et al even stated that “until high-level evidence demonstrates that routine surveillance with PET or PET/CT scans helps prolong life or promote wellbeing after treatment for a specific type of cancer, this practice should not be performed.”\textsuperscript{28} Given this recommendation, it is remarkable that an average of 1.6 CT scans were still performed on almost 10% of patients in their final month of life or an average of 0.6 times for almost 30% of patients during their final 3 months.

**Strengths and Limitations**

A major strength of our study was the analysis of the data at the level of health-care activities. Although our database only included hospital data, the use of these data enabled us to analyze HCU in detail. Furthermore, the involvement of a panel of medical experts enabled us to gather specialized input and opinions and subsequently understand and interpret the results. Our data were shown to be representative, as the mean age at death and the male–female ratio for both cancer types were comparable to the national mortality data.\textsuperscript{1}

Our study also had some limitations, such as the fact that we were not able to distinguish between curative and palliative treatments in these data. This is important, as it would give more insight into possible explanations for the HCU we have found in our study. Also, registered health care does not always necessarily reflect the actual health care supplied; faulty registrations or nonregistrations do occur. Furthermore, the 2015 database was not complete at the time of this study due to the time-consuming process of collecting data from Dutch hospitals. When comparing the data from each year, however, we found that our results were robust. We therefore argue that the incompleteness of the data did not substantially alter the image of the HCUP.

Although high-intensity hospital care is given to patients in the EoL phase, some patients received no hospital-based care. We were unable to investigate the differences in characteristics and HCU between these 2 groups, but we believe that the hospital-based patients are most likely to receive high-intensity and high-cost, maybe even inappropriate, care during the EoL phase in comparison to the nonhospital-based patients. We do not know whether the care for nonhospital-based patients was more appropriate than the hospital care provided to other patients. In order to further investigate this, any geographical or institutional variations in HCU within the Netherlands need to be identified, as these are even stronger indicators of potential overuse and underuse. We also need to broaden the scope of future studies by analyzing the full health-care chain to determine which types of primary care were provided for patients with high levels of secondary care utilization and to identify the underlying reasons for differences in HCU. The ultimate aim would be to signal the overuse and underuse of health care while also understanding it, leading to better conversations between physicians/institutions and patients to improve quality of care.

In conclusion, we observed a high usage of intense care in the EoL phase of patients with CRC and LC in the Netherlands, which may represent the overuse of health care, especially regarding hospital admissions and CT scans. Palliative care needs to be further improved and developed in the EoL phase and may currently be underused. Advanced care planning can play a substantial role in ensuring the appropriate use of palliative care. More research is necessary to identify the true overuse and underuse of hospital medical services.

**Authors’ Note**

The lead author affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

**Acknowledgments**

We gratefully thank all the experts involved in shaping our study and interpreting the results.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: This study was funded by the National Health Care Institute of the Netherlands. The funding organization did not participate in the design and conduct of the study; the analysis and interpretation of the data; the preparation, review, or approval of the manuscript; nor the decision to submit the manuscript for publication. They did participate in the collection and
management, and interpretation of the data as they are the processors of the data set. All researchers are independent of the funding party.

References

1. Integraal kankercentrum Nederland. Cijfers over kanker. 2016. http://www.cijfersoverkanker.nl/.
2. Volksgesondheid en zorg. 2015. https://www.volksgezondheiden.zorg.info/open-data-kosten-van-ziekten.
3. Bolt EE, Pasman HRW, Willems D, Onwuteaka-Philipsen BD. Appropriate and inappropriate care in the last phase of life: an explorative study among patients and relatives. *Bmc Health Serv Res.* 2016;16(1):655.
4. Gonsalves WI, Tashi T, Krishnamurthy J, et al. Effect of palliative care services on the aggressiveness of end-of-life care in the Veteran’s Affairs cancer population. *J Palliat Med.* 2011;14(11):1231-1235.
5. Martoni AA, Tanneberger S and Mutri V. Cancer chemotherapy near the end of life: the time has come to set guidelines for its appropriate use. *Tumori.* 2007;93(5):417.
6. Zhang B, Wright AA, Huskamp HA, et al. Health care costs in the last week of life: associations with end-of-life conversations. *Arch Intern Med.* 2009;169(5):480-488.
7. Bekelman JE, Halpern SD, Blankart CR, et al. Comparison of site of death, health care utilization, and hospital expenditures for patients dying with cancer in 7 developed countries. *JAMA.* 2016;315(3):272-283.
8. Zorgwijzer.nl. Cijfers en feiten over de zorgverzekering. 2015. https://www.zorgwijzer.nl/zorgverzekering-2016/cijfers-en-feiten-over-zorgverzekering. Accessed September 2017.
9. Nederlandse Zorgautoriteit. Werken met dbc’s ziekenhuiszorg. http://werkenmetdbcs.nza.nl/zz-releases/algemeen-4/rz13d/menu-ID-1938 (2013, 2016).
10. Teno JM, Gozalo PL, Bynum JP, et al. Change in end-of-life care for Medicare beneficiaries: site of death, place of care, and health care transitions in 2000, 2005, and 2009. *JAMA.* 2013;309(3):470-477.
11. Buiting HM, Rurup ML, Wijsbek H, et al. Understanding provision of chemotherapy to patients with end stage cancer: qualitative interview study. *BMJ.* 2011;342:d1933.
12. Brom L, De Snoo-Trim JC, Onwuteaka-Philipsen BD, et al. Challenges in shared decision making in advanced cancer care: a qualitative longitudinal observational and interview study. *Health Expect.* 2017;20(1):69-84.
13. Emanuel LL, von Gunten CF and Ferris FD. Advance care planning. *Arch Fam Med.* 2000;9(10):1181-1187.
14. Detering KM, Hancock AD, Reade MC, Silvester W. The impact of advance care planning on end of life care in elderly patients: randomised controlled trial. *BMJ.* 2010;340(7751): c1345.
15. Silveira MJ, Kim SY, Langa KM. Advance directives and outcomes of surrogate decision making before death. *New Engl J Med.* 2010;362(13):1211-1218.
16. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non–small-cell lung cancer. *New Engl J Med.* 2010;363(8):733-742.
17. Greer JA, Pirl WF, Jackson VA, et al. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non–small-cell lung cancer. *J Clin Oncol.* 2011;30(4):394-400.
18. DiMartino LD, Weiner BJ, Mayer DK, Jackson GL, Biddle AK. Do palliative care interventions reduce emergency department visits among patients with cancer at the end of life? A systematic review. *J Palliat Med.* 2014;17(12):1384-1399.
19. Boddaert M, Douma J, Aalst van B, et al. Palliatieve zorg in Nederlandse ziekenhuizen. Resultaten 2015. Utrecht, the Netherlands: IKNL; 2015.
20. Brinkman-Stoppelenburg A, Rietjens JA, van der Heide A. The effects of advance care planning on end-of-life care: a systematic review. * Palliative Med.* 2014. doi: 10.1177/0269216314526272.
21. Oosterveld-Vlug M, Donker G, Atsma F, et al. How do treatment aims in the last phase of life relate to hospitalizations and hospital mortality? A mortality follow-back study of Dutch patients with five types of cancer. *Support Care Cancer* 2018;26(3):777-786.
22. Connor SR, Pyenson B, Fitch K, Spence C, Iwasaki K. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. *J Pain Symptom Manag* 2007;33(3):238-246.
23. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non–small-cell lung cancer. *N Engl J Med.* 2005;353(2):123-132.
24. Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. *Onco logically.* 2007;12(1):38-50.
25. Gomes B, Higginson IJ, Calanzani N, et al. Preferences for place of death if faced with advanced cancer: a population survey in England, Flanders, Germany, Italy, the Netherlands, Portugal and Spain. *Ann Oncol.* 2012;23(8):2006-2015.
26. Ko W, Beccaro M, Miccinesi G, et al. Awareness of general practitioners concerning cancer patients’ preferences for place of death: evidence from four European countries. *Eur J Cancer.* 2013;49(8):1967-1974.
27. Verboom P, van Tinteren H, Hoekstra OS, et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. *Eur J Nucl Med Mol Imag.* 2003;30(11):1444-1449.
28. Schnipper LE, Lyman GH, Blayne DW, et al. American Society of Clinical Oncology 2013 top five list in oncology. *J Clin Oncol.* 2013;31(34):4362-4370.